MD Anderson Therapeutics Discovery team identifies and advances a drug that targets metabolic vulnerability and impairs cancer cell growth and survival

(University of Texas M. D. Anderson Cancer Center) A drug discovered and advanced by The University of Texas MD Anderson Cancer Center's Institute for Applied Cancer Science (IACS) and the Center for Co-Clinical Trials (CCCT) inhibits a vital metabolic process required for cancer cells' growth and survival.

Comments